Healthpeak Properties has delivered a 29.0% return over the past year, yet there is a split between what its current share price suggests and what an intrinsic value estimate and broader valuation checks imply. The Discounted Cash Flow (DCF) intrinsic value estimate indicates meaningful upside from the current market price, while earnings-based multiples point to an overvalued stock and the overall value score is on the weak side.

• Over the past 1 year, Healthpeak Properties has returned 29.0%, which puts recent shareholders in a strong position and raises the bar for further upside.
• Future cash flow growth from its real estate portfolio can support the intrinsic value case, while any pressure on occupancy, rental yields or funding costs may limit how much of that value is realised.
• On Simply Wall St's broader checks, Healthpeak Properties scores 2 out of 6 on valuation, which leans expensive rather than a clear bargain.

For investors, the debate is whether Healthpeak Properties is closer to the upside suggested by the Discounted Cash Flow intrinsic value estimate, which points to the stock trading about 45.3% below that value, or to the richer picture implied by current market multiples and its low value score.

Does Healthpeak Properties Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Healthpeak Properties based on the cash its real estate portfolio is expected to generate over time. The company has latest twelve month free cash flow of about $1.29b, and the model assumes broadly growing but steady cash flows from here rather than sharp swings.

On those assumptions, the DCF framework points to an estimated intrinsic value of about $37.76 per share. Compared with the current market price, that implies Healthpeak Properties trades at a discount of roughly 45.3%, which indicates the stock appears undervalued on this cash flow view.

On the DCF numbers alone, Healthpeak Properties appears undervalued relative to what its projected cash flows support.

Our Discounted Cash Flow (DCF) analysis suggests Healthpeak Properties is undervalued by 45.3%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Is Healthpeak Properties Getting Expensive on Earnings?

P/E is a useful lens for Healthpeak Properties because earnings are a key anchor for how investors price real estate investment trusts. Healthpeak Properties currently trades on a P/E of about 58.7x, which is well above the Health Care REITs industry average of roughly 17.0x and higher than the peer average of about 45.8x.

The model based fair P/E ratio for Healthpeak Properties is about 20.8x. This reflects what might be expected given its size, risk profile and sector. The gap between this fair ratio and the current 58.7x suggests investors are paying a rich price for each dollar of earnings compared with both sector norms and the tailored fair multiple.

On the P/E multiple, Healthpeak Properties stock appears overvalued relative to both its fair ratio and industry benchmarks.

The Healthpeak Properties Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Healthpeak Properties pick up from this valuation split and explain which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today's price. These narratives are available on the company’s Community page. Each one links its valuation to a clear view of how Healthpeak Properties' growth, profitability and risks might change over time, which you can revisit as new information becomes available.

Community views on Healthpeak Properties sit far apart, with one side focused on upside from operational change and the other on pressure from tenant and funding risks.

Bull case: 24% undervalued

"Healthpeak's unique, high-concentration positions in premier high-growth Sunbelt and innovation markets, deep health system relationships, and a war chest for opportunistic acquisitions in a distressed competitive landscape, mean future accretive investments could drive a step-change in AFFO per share growth as capital market conditions shift, well ahead of consensus expectations…"

Bear case: 17% overvalued

"Although Healthpeak Properties benefits from sustained demand drivers such as the aging U.S. population and the ongoing shift toward outpatient care, the company faces potential revenue headwinds from execution risk and occupancy volatility within its life science segment, as smaller biotech tenants continue to struggle accessing capital, which may drive elevated vacancy rates and rent concessions in the near to medium term…"

Do you think there's more to the story for Healthpeak Properties? Head over to our Community to see what others are saying!

The Bottom Line

Healthpeak Properties sits between a Discounted Cash Flow (DCF) intrinsic value estimate that flags undervalued, and earnings multiples that screen as overvalued. The gap largely reflects different views on future cash flows, funding needs and how much investors are willing to pay for its earnings profile. With broader valuation checks still on the weak side, the key question is whether cash flows from the portfolio ultimately converge toward the intrinsic value case or whether the rich P/E better reflects the risks around occupancy, rents and capital costs. That tension is what will matter most for where Healthpeak Properties goes next.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.